DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > University Hospital > Articles in academic journal >

悪性胸膜中皮腫に対するペメトレキセドの実臨床における有用性の検討


File Description SizeFormat
haigan52_4_371.pdf234.94 kBAdobe PDFView/Open

Title: 悪性胸膜中皮腫に対するペメトレキセドの実臨床における有用性の検討
Other Titles: A Clinical Study of 34 Malignant Pleural Mesothelioma Patients Treated with Pemetrexed from Nagasaki Thoracic Oncology Group
Authors: 池田, 喬哉 / 中村, 洋一 / 福田, 実 / 福田, 正明 / 早田, 宏 / 木下, 明敏 / 副島, 佳文 / 河野, 茂
Authors (alternative): Ikeda, Takaya / Nakamura, Yoichi / Fukuda, Minoru / Fukuda, Masaaki / Soda, Hiroshi / Kinoshita, Akitoshi / Soejima, Yoshifumi / Kohno, Shigeru
Issue Date: 21-Sep-2012
Publisher: 日本肺癌学会 / Japan Lung Cancer Society
Citation: 肺癌, 52(4), pp.371-374; 2012
Abstract: 目的.悪性胸膜中皮腫に対するペメトレキセドを含む化学療法の効果と有害事象についてレトロスペクティブな検討を行った.方法.2007年2月~2009年12月に長崎胸部腫瘍研究グループ関連施設においてペメトレキセドを含む化学療法を行った悪性胸膜中皮腫34例を検討.結果.男性28例,女性6例,年齢中央値68歳(53~81歳)でアスベスト曝露があった症例は26例.病理組織型は上皮型16例,肉腫型10例,二相型5例,不明3例であった.初回化学療法25例,既治療8例,30例がペメトレキセド・シスプラチン併用療法,3例がペメトレキセド・カルボプラチン併用療法,1例がペメトレキセド単剤療法を受けていた.ペメトレキセド(500 mg/m2)・シスプラチン(75 mg/m2)併用療法を受けた24例のGrade 3以上の毒性は白血球減少2例(8.3%),好中球減少5例(20.8%),消化器毒性2例(8.3%)で,奏効率12.5%,生存期間中央値14.4ヶ月であった.結論.実臨床でのペメトレキセド・シスプラチン併用療法の効果と有害事象は,過去の前向き試験の結果とほぼ同程度であった. / Objective. We analyzed the clinical features and outcomes of malignant pleural mesothelioma patients treated with pemetrexed. Method. From February 2007 to December 2009, 34 patients enrolled with the Nagasaki Thoracic Oncology Group were treated with pemetrexed. Results. Of the 34 patients, 28 were men and 6 were women with a median age of 68 years old (range 53 to 81). Twenty-six patients (76.5%) had exposed to asbestos. The histological subtype was epithelioid in 16 patients, sarcomatoid in 10 patients, biphasic in 5 patients, unknown in 3 patients. Twenty-five patients were chemotherapy-naive patients and 8 patients had received prior chemotherapy. Thirty patients had received pemetrexed and cisplatin chemotherapy. Three patients had received pemetrexed and carboplatin chemotherapy. One patient had received pemetrexed monotherapy. In pemetrexed (500 mg/m 2) and cisplatin (75 mg/m 2) group, grade 3 or 4 leukocytopenia was recorded in 2 patients (8.3%), grade 3 or 4 neutropenia was recorded in 5 patients (20.8%), grade 3 or 4 gastrointestinal toxicities were recorded in 2 patients (8.3%). The response rate was 12.5%, the median survival was 14.4 months. Conclusion. In this study clinical efficacy and toxicities of malignant pleural mesothelioma patients treated with pemetrexed and cisplatin chemotherapy are comparable to previous prospective studies.
Keywords: Chemotherapy / Cisplatin / Malignant pleural mesothelioma / Pemetrexed
URI: http://hdl.handle.net/10069/30608
ISSN: 03869628
DOI: 10.2482/haigan.52.371
Rights: © 2012 日本肺癌学会
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/30608

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace